NCT01263951Unknown2 期
A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- To determine the efficacy of everolimus and sorafenib (progression free survival, objective response rate and stable disease) in patients with advanced differentiated thyroid cancer who have progressed on sorafenib alone.
研究概览
简要总结
The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
详细描述
The purpose of this research study is to:
- Find out if sorafenib and everolimus prevent the growth of tumors that have grown when treated with sorafenib alone
- Find out how long one might benefit from treatment with sorafenib and everolimus
- Find out what side effects this drug may cause
- Measure the amount of sorafenib and everolimus in the blood and see if "markers" can be found to help understand who might benefit from sorafenib and everolimus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 89 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of thyroid cancer, that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
- •All patients will have been required to have had sorafenib for entry and have had documented progression while on previous treatment with sorafenib.
- •Measurable disease defined as at least one malignant lesion that can be accurately measured on computerized tomography (CT) and/or magnetic resonance imaging (MRI) scan.
- •ECOG performance status <
- •Life expectancy greater than 3 months.
- •Intellectual, emotional, and physical ability to comply with oral medication.
排除标准
- •Restrictions regarding certain prior treatments will apply.
- •Significant medical disease including: uncontrolled congestive heart failure; active symptoms of coronary artery disease, uncontrolled seizure disorder; active infection; uncontrolled diabetes mellitus; requirement for chronic high dose corticosteroid treatment (Topical or inhaled corticosteroids are allowed); requirement for concurrent immunosuppressive drug(s); active autoimmune disease.
- •Organ allografts.
- •Known HIV-infection (HIV testing is not required for participation).
- •Pregnant or breast feeding. Women of childbearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment
- •History of second cancer (except adequately treated basal cell or squamous cell skin cancer, in situ treated cervical cancer, colon cancer or melanoma, or any other cancer for which the patient has been disease-free for three or more years).
- •Known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus, temsirolimus) or to its excipients
- •Use of any experimental therapy within 4 weeks prior to baseline evaluations done prior to enrollment (with the exception of sorafenib which may be continued until treatment start). Therefore, all experimental treatments other than sorafenib must be discontinued 4 weeks prior to baseline studies or enrollment.
- •Patients who did not previously tolerate sorafenib at 200 mg once daily are excluded from the study.
研究组 & 干预措施
Everolimus and sorafenib
Experimental
All patients will receive everolimus and sorafenib daily.
干预措施: Everolimus (Drug)
Everolimus and sorafenib
Experimental
All patients will receive everolimus and sorafenib daily.
干预措施: Sorafenib (Drug)
结局指标
主要结局
To determine the efficacy of everolimus and sorafenib (progression free survival, objective response rate and stable disease) in patients with advanced differentiated thyroid cancer who have progressed on sorafenib alone.
时间窗: Every 4 weeks
次要结局
- To evaluate the activity of additional signaling pathways in surrogate tissue and tumor samples and explore their relevance to outcome measures.(Every 4 weeks)
- To evaluate the secondary endpoints of best response in patients receiving everolimus and sorafenib.(Every 4 weeks)
- To investigate the effectiveness of mTOR and Raf kinase inhibition in surrogate tissue and tumor samples.(Every 4 weeks)
- To evaluate the secondary endpoints of time to disease progression in patients receiving everolimus and sorafenib.(Every 4 weeks)
- To evaluate the secondary endpoints of duration of response in patients receiving everolimus and sorafenib.(Every 4 weeks)
- To perform correlative scientific studies to determine the relationship between clinical response to everolimus and sorafenib and multiple parameters including the mutational status of BRAF, N-RAS and other relevant cancer genes in the tumor.(Every 4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine HydrochlorideAcinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00981162Roswell Park Cancer Institute12
进行中（未招募）
2 期
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid CancerRefractory Hurthle Cell Thyroid CancerNCT02143726Alliance for Clinical Trials in Oncology35
进行中（未招募）
2 期
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid CancerThyroid CancerNCT01141309Memorial Sloan Kettering Cancer Center41
已完成
2 期
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain TumorNCT00445588National Cancer Institute (NCI)56
已完成
1 期
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasAnaplastic GliomaGlioblastomaBrain TumorNCT01434602National Cancer Institute (NCI)86